- Home
- / Caribou Biosciences
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Caribou Biosciences financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.9
2024-10-04
Market Capitalization
$169 M
2024-10-04
Revenue
$34.5 M
FY, 2023
CreditSafe Score
?
Score changed on Oct 13, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|
| Revenue | 9.6M | 13.9M | 34.5M |
| General and administrative expense | 24.3M | 38.0M | 38.5M |
| Operating expense total | 76.6M | 120.3M | |
| EBIT | (67.0M) | (106.4M) | (116.1M) |
| EBIT margin, % | -697.8% | -768.2% | |
| Interest income | 148.0K | ||
| Interest expense | 8.0K | ||
| Pre tax profit | (66.6M) | (99.4M) | (101.9M) |
| Income tax expense | 321.0K | 70.0K | 193.0K |
| Net Income | (66.9M) | (99.4M) | (102.1M) |
| EPS | (1.6) | (1.0) |